Helsinn Named as One of the Best Places to Work in New Jersey by NJBIZ

Bridgewater, NJ (ots) - Helsinn Group, the company focused on
building quality cancer care, is pleased to announce today that its
U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc., has been named as
one of the 100 best places to work in New Jersey in a survey and
award program conducted by NJBIZ which recognizes and honors the
state's top employers who show a dedication to their employees'
growth and quality of life.

In 2009 Helsinn acquired the U.S. biotech company Sapphire
Therapeutics Inc., to establish the U.S.-based R&D and commercial
operation Helsinn Therapeutics (U.S.), Inc., located in Bridgewater,
New Jersey. This business venture has expanded Helsinn's pipeline of
products in existing focus therapeutic areas and, through the
venture, the Helsinn Group is now in a position to operate directly
in the U.S. market with a direct sales structure within the U.S.
cancer care community.

The 100 Best Places to Work in New Jersey ranking was a two-part
process with part one evaluating each nominated company's workplace
policies, practices, philosophy, systems and demographics and part
two consisting of an employee survey to measure the staff experience.
The award program, created in 2005, will announce ranking during an
awards dinner and ceremony on Thursday, May 1, 2014, at the Hyatt New
Brunswick. The program sponsors include Gibbons P.C., Novo Nordisk
and MetLife Solutions Group and is run in partnership with Garden
State Council SHRM and Employers Association of New Jersey.

For more information on the Best Places to Work in New Jersey
program please visit www.njbiz.com/BestPlacesNJ

About the Helsinn Group

Helsinn is a family run, privately owned pharmaceutical group
focused on building quality cancer care with a large portfolio of
products. Founded in 1976 with headquarters in Lugano, Switzerland,
Helsinn also has operating subsidiaries in Ireland, the U.S. and a
Representative Office in China. Helsinn's business model is focused
on the licensing of pharmaceuticals, medical devices and nutritional
supplement products in the therapeutic area of cancer care. Helsinn
Group in-licenses early-to-late stage new chemical entities,
completing their development by performing preclinical and clinical
studies and associated manufacturing activities. Helsinn then
prepares necessary regulatory filings in order to achieve marketing
approvals worldwide. Helsinn's products are out-licensed to its
global network of marketing and commercial partners that have been
selected for their local market knowledge. Helsinn supports these
partners by providing a full range of product and scientific
management services, including commercial, regulatory, and medical
marketing advice. In March 2013, Helsinn established a new commercial
organization within its subsidiary, Helsinn Therapeutics (U.S.),
Inc., in order to conduct direct sales and marketing activities
within the U.S. market. Helsinn's products are manufactured according
to the highest quality, safety, and environmental standards at
Helsinn's GMP facilities in Switzerland and Ireland from where they
are then supplied worldwide to customers. Further information on
Helsinn Group is available at www.helsinn.com

For more information, please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
Tel: +41 91-985-21-21
info-hhc@helsinn.com

For media / external inquiries
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Melissa Jumbo
Tel: +44 (0)203 709 5700
Helsinn@consilium-comms.com